# Ollin Biosciences

> Ollin Biosciences is an Austin-based clinical-stage biopharmaceutical company building a portfolio of best-in-disease therapies for vision-threatening eye diseases. Founded in 2023 and launched publicly in September 2025 with $100M in Series A financing, Ollin in-licenses validated drug candidates and races them through head-to-head trials against the market leaders. Its lead program, OLN324, is a VEGF/Ang2 bispecific antibody for wet age-related macular degeneration and diabetic macular edema that posted superior anatomic results versus Roche's blockbuster Vabysmo in a Phase 1b study.

- **Founded:** 2023
- **Headquarters:** Austin, United States
- **Founders:** Jason Ehrlich (Co-Founder & CEO), Atul Dandekar (Co-Founder)
- **Team size:** ~19 employees
- **Products:** OLN324 (IBI324), OLN102
- **Notable:** Launched from stealth in September 2025 with $100M in Series A financing., Reported positive Phase 1b JADE topline data (January 2026) showing OLN324 with superior anatomic efficacy versus the market leader faricimab., Nearly 90% of OLN324 4mg DME patients achieved absence of edema at Week 12 vs 57% with faricimab.

## Products & services

- **OLN324 (IBI324)** — A VEGF/Ang2 bispecific antibody for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). In-licensed from Innovent Biologics. Up to 60-fold higher anti-Ang2 potency with a smaller protein format and higher molar dose. In the Phase 1b JADE study it showed superior anatomic drying versus faricimab (Vabysmo). Global Phase 3 trials planned for 2026.
- **OLN102** — A first-in-class TSHR/IGF-1R bispecific antibody targeting thyroid eye disease and Graves' disease, in-licensed from VelaVigo. Designed as an alternative to Amgen's Tepezza with an improved safety profile and subcutaneous dosing. Expected to enter clinical development in 2026.

## Achievements

- Launched from stealth in September 2025 with $100M in Series A financing.
- Reported positive Phase 1b JADE topline data (January 2026) showing OLN324 with superior anatomic efficacy versus the market leader faricimab.
- Nearly 90% of OLN324 4mg DME patients achieved absence of edema at Week 12 vs 57% with faricimab.
- No intraocular inflammation cases observed with OLN324 in the JADE study.
- Assembled a leadership team and scientific advisory board drawn from Genentech, Kodiak Sciences, and top retinal institutions.

## Latest updates

- **2026-01** — Announced positive topline Phase 1b JADE data: OLN324 showed superior retinal drying versus faricimab in DME and equivalent outcomes in wAMD, with a clean inflammation profile. Global Phase 3 trials planned for 2026.
- **2026-01** — Scheduled to present at the J.P. Morgan Healthcare Conference (Jan 13) and full JADE results at the Angiogenesis, Exudation, and Degeneration 2026 symposium (Feb 7).
- **2025-09** — Emerged from stealth with a $100M Series A led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital, unveiling its OLN324 and OLN102 pipeline.

## Links

- Website: https://ollin.bio
- LinkedIn: https://www.linkedin.com/company/ollin-biosciences
- Twitter/X: https://x.com/OllinBio

---

Profile page: https://yespress.io/ollin-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-06-13